The pathway through LC-MS method development : in-house or ready-to-use kit-based methods?
Historically, the determination of low concentration analytes was initially made possible by the development of rapid and easy-to-perform immunoassays (IAs). Unfortunately, typical problems inherent to IA technologies rapidly appeared (e.g. elevated cost, cross-reactivity, lot-to-lot variability, etc.). In turn, liquid chromatography tandem mass spectrometry (LC-MS/MS) methods are sensitive and specific enough for such analyses. Therefore, they would seem to be the most promising candidates to replace IAs. There are two main choices when implementing a new LC-MS/MS method in a clinical laboratory: (1) Developing an in-house method or (2) purchasing ready-to-use kits. In this paper, we discuss some of the respective advantages, disadvantages and mandatory requirements of each choice. Additionally, we also share our experiences when developing an in-house method for cortisol determination and the implementation of an "ready-to-use" (RTU) kit for steroids analysis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:58 |
|---|---|
| Enthalten in: |
Clinical chemistry and laboratory medicine - 58(2020), 6 vom: 25. Juni, Seite 1002-1009 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Le Goff, Caroline [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
In-house method |
|---|
| Anmerkungen: |
Date Completed 19.08.2021 Date Revised 19.08.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1515/cclm-2019-0916 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM306631997 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM306631997 | ||
| 003 | DE-627 | ||
| 005 | 20231225123811.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1515/cclm-2019-0916 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1022.xml |
| 035 | |a (DE-627)NLM306631997 | ||
| 035 | |a (NLM)32069223 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Le Goff, Caroline |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The pathway through LC-MS method development |b in-house or ready-to-use kit-based methods? |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.08.2021 | ||
| 500 | |a Date Revised 19.08.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Historically, the determination of low concentration analytes was initially made possible by the development of rapid and easy-to-perform immunoassays (IAs). Unfortunately, typical problems inherent to IA technologies rapidly appeared (e.g. elevated cost, cross-reactivity, lot-to-lot variability, etc.). In turn, liquid chromatography tandem mass spectrometry (LC-MS/MS) methods are sensitive and specific enough for such analyses. Therefore, they would seem to be the most promising candidates to replace IAs. There are two main choices when implementing a new LC-MS/MS method in a clinical laboratory: (1) Developing an in-house method or (2) purchasing ready-to-use kits. In this paper, we discuss some of the respective advantages, disadvantages and mandatory requirements of each choice. Additionally, we also share our experiences when developing an in-house method for cortisol determination and the implementation of an "ready-to-use" (RTU) kit for steroids analysis | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a in-house method | |
| 650 | 4 | |a kit ready to use | |
| 650 | 4 | |a mass spectrometry | |
| 700 | 1 | |a Farre-Segura, Jordi |e verfasserin |4 aut | |
| 700 | 1 | |a Stojkovic, Violeta |e verfasserin |4 aut | |
| 700 | 1 | |a Dufour, Patrice |e verfasserin |4 aut | |
| 700 | 1 | |a Peeters, Stéphanie |e verfasserin |4 aut | |
| 700 | 1 | |a Courtois, Justine |e verfasserin |4 aut | |
| 700 | 1 | |a Nizet, Adrien |e verfasserin |4 aut | |
| 700 | 1 | |a De Vos, Nathalie |e verfasserin |4 aut | |
| 700 | 1 | |a Cavalier, Etienne |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical chemistry and laboratory medicine |d 1998 |g 58(2020), 6 vom: 25. Juni, Seite 1002-1009 |w (DE-627)NLM095304118 |x 1437-4331 |7 nnns |
| 773 | 1 | 8 | |g volume:58 |g year:2020 |g number:6 |g day:25 |g month:06 |g pages:1002-1009 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1515/cclm-2019-0916 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 58 |j 2020 |e 6 |b 25 |c 06 |h 1002-1009 | ||